SOX combined with intraperitoneal perfusion of docetaxel compared with DOS regimen in the first-line therapy for advanced gastric cancer with malignant ascites: a prospective observation

被引：0
|
作者：
Yehong Bin
Dong Lan
Wenguang Bao
Haiyan Yang
Shengsheng Zhou
Fengxiang Huang
Man Wang
Zhigang Peng
机构：
[1] the First Affiliated Hospital of Guangxi Medical University,Department of Oncology
来源：
Trials | / 23卷
关键词：
Advanced gastric cancer; Malignant ascites; Intraperitoneal infusion of chemotherapy; First-line chemotherapy; Docetaxel; S-1; Oxaliplatin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] A randomized phase II study of weekly docetaxel/cisplatin versus weekly docetaxel/oxaliplatin as first-line therapy for patients with advanced gastric cancer
    Young Saing Kim
    Sun Jin Sym
    Se Hoon Park
    Inkeun Park
    Junshik Hong
    Hee Kyung Ahn
    Jinny Park
    Eun Kyung Cho
    Woon Ki Lee
    Min Chung
    Jae Hoon Lee
    Dong Bok Shin
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 163 - 169
  • [22] Combining cetuximab with FOLFOX regimen as the first-line therapy of KRAS wild-type advanced gastric cancer.
    Yeh, Yung-Sung
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [23] Apatinib combined with SOX regimen for conversion therapy in advanced gastric cancer patients: a retrospective cohort study
    Deng, Ya-Ya
    Jiang, Ding-Yi
    Zhu, Peng-Fei
    Lu, Hongrui
    Liu, Qian
    Zhang, Xinyue
    Pan, Shuang-Yue
    Chen, Zhe-Ling
    Yang, Liu
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2023, 21 (01)
  • [24] Apatinib combined with SOX regimen for conversion therapy in advanced gastric cancer patients: a retrospective cohort study
    Ya-Ya Deng
    Ding-Yi Jiang
    Peng-Fei Zhu
    Hongrui Lu
    Qian Liu
    Xinyue Zhang
    Shuang-Yue Pan
    Zhe-Ling Chen
    Liu Yang
    World Journal of Surgical Oncology, 21
  • [25] Advanced gastric cancer New therapy option for first-line therapy in clinical development
    Koczorek, Michael
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 (1-2)
  • [26] Capecitabine in combination with Oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer
    Yeon Hee Park
    Jae-Lyun Lee
    Baek-Yeol Ryoo
    Min-Hee Ryu
    Sung Hyun Yang
    Bong Seog Kim
    Dong Bok Shin
    Heung Moon Chang
    Tae Won Kim
    Young Jin Yuh
    Yoon-Koo Kang
    Cancer Chemotherapy and Pharmacology, 2008, 61 : 623 - 629
  • [27] Capecitabine in combination with Oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer
    Park, Yeon Hee
    Lee, Jae-Lyun
    Ryoo, Baek-Yeol
    Ryu, Min-Hee
    Yang, Sung Hyun
    Kim, Bong Seog
    Shin, Dong Bok
    Chang, Heung Moon
    Kim, Tae Won
    Yuh, Young Jin
    Kang, Yoon-Koo
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 61 (04) : 623 - 629
  • [28] A dose-escalation study of docetaxel, oxaliplatin, and S-1 (DOS) as a first-line therapy for patients with unresectable metastatic gastric cancer
    Yasushi Sato
    Tamotsu Sagawa
    Hiroyuki Ohnuma
    Masahiro Hirakawa
    Yasuo Takahashi
    Kyoko Hamaguchi
    Koshi Fujikawa
    Takayuki Nobuoka
    Koichi Okamoto
    Hiroshi Miyamoto
    Naoki Muguruma
    Ichiro Takemasa
    Tetsuji Takayama
    Cancer Chemotherapy and Pharmacology, 2019, 83 : 161 - 167
  • [29] A dose-escalation study of docetaxel, oxaliplatin, and S-1 (DOS) as a first-line therapy for patients with unresectable metastatic gastric cancer
    Sato, Yasushi
    Sagawa, Tamotsu
    Ohnuma, Hiroyuki
    Hirakawa, Masahiro
    Takahashi, Yasuo
    Hamaguchi, Kyoko
    Fujikawa, Koshi
    Nobuoka, Takayuki
    Okamoto, Koichi
    Miyamoto, Hiroshi
    Muguruma, Naoki
    Takemasa, Ichiro
    Takayama, Tetsuji
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 83 (01) : 161 - 167
  • [30] Combination therapy with docetaxel and S-1 as a first-line treatment in patients with advanced or recurrent gastric cancer: a retrospective analysis
    Kazuaki Tanabe
    Takahisa Suzuki
    Noriaki Tokumoto
    Hideki Yamamoto
    Kazuhiro Yoshida
    Hideki Ohdan
    World Journal of Surgical Oncology, 8
12345